Nirogy News

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of cancer cells in both in vitro and in vivo models Boston, April 7, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced that …

Nirogy Therapeutics to Present at AACR Annual Meeting 2021 Read More »

Nirogy Therapeutics Launches with $16.5 Million Series A Financing

Boston, Massachusetts.  January 26, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the closing of a $16.5 million Series A financing. The financing was co-led by Santé Ventures and Sporos. In conjunction with the financing, Dennis McWilliams of Santé and Joseph Kekst of Sporos …

Nirogy Therapeutics Launches with $16.5 Million Series A Financing Read More »

Scroll to Top